Skip to main content

Table 1 Demographics, clinical characteristics, and laboratory findings of COVID-19 patients

From: Correlation between lung infection severity and clinical laboratory indicators in patients with COVID-19: a cross-sectional study based on machine learning

Characteristics  
Age, years 42.6 ± 16.0
  < 40 16 (51.6%)
 40–60 12 (38.7%)
  > 60 3 (9.7%)
Sex
 Female 13 (41.9%)
 Male 18 (58.1%)
Hypertension/ diabetes /cardiovascular disease/ cerebrovascular disease/COPD/kidney disease 8 (25.8%)
Signs and symptoms
 Fever 29 (93.5%)
 Cough 15 (48.4%)
 Fatigue 2 (6.5%)
 Myalgia 1 (3.2%)
 Diarrhea 1 (3.2%)
Interval from illness onset to CT scan, days 8.8 ± 5.7
Days of clinical intervention before CT scan 2.6 ± 3.5
Proportion of affected lungs calculated by AI (%) 8.91 ± 15.01
  < 5% 21 (67.7%)
 5–20% 5 (16.1%)
  > 20% 5 (16.1%)
Clinical classification according to ncpDTP-7
 Mild 0 (0.0%)
 Moderate 23 (74.2%)
 Severe 4 (12.9%)
 Critical 4 (12.9%)
Arterial blood gas on the day of CT scan
 PaO2, mmHg 57.7 ± 19.8
  < 60 4/6 (66.7%)
  ≥ 60 2/6 (33.3%)
 PaCO2, mmHg 42.7 ± 6.8
  ≤ 50 5/6 (83.3%)
  > 50 1/6 (16.7%)
Laboratory findings
 White blood cell count, × 109/L 4.80 ± 1.87
  < 4 13 (41.9%)
 4–10 17 (54.8%)
  > 10 1 (3.2%)
 Lymphocyte percentage (%) 30.3 ± 13.3
 Lymphocyte count, ×109/L 1.35 ± 0.59
 Neutrophil percentage (%) 57.4 ± 14.1
 Monocyte percentage (%) 11.0 ± 3.7
 Hemoglobin, g/L 131.4 ± 18.1
 AST, U/L 35.3 ± 28.6
  ≤ 40 21/30 (70.0%)
  > 40 9 /30 (30.0%)
 ALT, U/L 26.7 ± 18.4
  ≤ 35 25/30 (83.3%)
  > 35 5 /30 (16.7%)
 CRP, mg/L 19.2 ± 30.1
  ≤ 5 10/21 (47.6%)
  > 5 11/21 (52.4%)
 CK, U/L 148.3 ± 271.9
  ≤ 200 25/28 (89.3%)
  > 200 3/28 (10.7%)
  1. Continues data are expressed as mean ± SD. Categorical data are presented as n (%) or n/N (%), where N is the total number of patients with available data
  2. Abbreviations: COVID-19 coronavirus disease 2019, COPD chronic obstructive pulmonary disease, CT computer tomography, AI artificial intelligence, ncpDTP-7 new coronavirus pneumonia diagnosis and treatment plan (trial version 7), AST aspartate transaminase, ALT alanine transaminase, CRP C-reactive protein, CK creatine kinase
\